{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:27:07Z","timestamp":1790274427677,"version":"4.1.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T00:00:00Z","timestamp":1709942400000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000646","name":"Japan Society for the Promotion of Science London","doi-asserted-by":"publisher","award":["JP23K15254"],"award-info":[{"award-number":["JP23K15254"]}],"id":[{"id":"10.13039\/501100000646","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,30]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The mechanism leading to the development of immunoglobulin A nephropathy (IgAN) remains to be completely understood. Endothelin-1 (ET-1) as well as angiotensin II (AngII) promote glomerular injury, tubulointerstitial inflammation and fibrosis leading to chronic kidney disease. Sparsentan, a dual endothelin angiotensin receptor antagonist, recently received accelerated approval in the USA for the reduction of proteinuria in adults with IgAN at high risk of disease progression. To elucidate the mechanisms by which sparsentan is efficacious in IgAN, we examined the effect of treatment in gddY mice, a spontaneous IgAN mouse model, versus the monoselective angiotensin II type 1 receptor (AT1R) antagonist, losartan, on the development of renal injury at doses resulting in similar blood pressure lowering.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Four-week-old gddY mice were given control chow, chow containing sparsentan or drinking water containing losartan until 12 or 20 weeks old.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Remarkably, the albumin:creatine ratio (ACR) was attenuated more rapidly and to a greater extent in mice treated with sparsentan than those treated with losartan. The decrease in ACR from baseline after 4 weeks of treatment correlated with beneficial effects of sparsentan on glomerulosclerosis and protection of podocytes and glycocalyx after 16 weeks of treatment across treatment groups; thus, sparsentan treatment delayed development of renal injury to a greater extent than losartan. Expression of mRNA for ET-1, endothelin type A receptor and AT1R and proinflammatory genes was upregulated in 12-week-old gddY mice and was prevented by sparsentan and losartan to a comparable extent.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The results of this study, and in light of the results of the phase 3 PROTECT trial, provide a novel perspective and understanding of the mechanisms by which sparsentan has a beneficial renoprotective effect against IgAN compared with AT1R antagonism alone.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ndt\/gfae021","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T19:55:56Z","timestamp":1706212556000},"page":"1494-1503","source":"Crossref","is-referenced-by-count":36,"title":["Sparsentan is superior to losartan in the gddY mouse model of IgA nephropathy"],"prefix":"10.1093","volume":"39","author":[{"given":"Hajime","family":"Nagasawa","sequence":"first","affiliation":[{"name":"Department of Nephrology, Juntendo University Faculty of Medicine , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Juntendo University Faculty of Medicine , Tokyo , Japan"},{"name":"Division of Kidney Health and Aging, Center for Integrated Kidney Research Advance, Shimane University Faculty of Medicine , Izumo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Juntendo University Faculty of Medicine , Tokyo , Japan"},{"name":"Department of Nephrology, Juntendo University Urayasu Hospital , Chiba , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Jenkinson","sequence":"additional","affiliation":[{"name":"Travere Therapeutics, Inc. , San Diego, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Fukao","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Juntendo University Faculty of Medicine , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiko","family":"Nakayama","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Juntendo University Faculty of Medicine , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Otsuka","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Juntendo University Faculty of Medicine , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruyuki","family":"Okuma","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Juntendo University Faculty of Medicine , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilmelenne","family":"Clapper","sequence":"additional","affiliation":[{"name":"Travere Therapeutics, Inc. , San Diego, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Liu","sequence":"additional","affiliation":[{"name":"Travere Therapeutics, Inc. , San Diego, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Travere Therapeutics, Inc. , San Diego, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radko","family":"Komers","sequence":"additional","affiliation":[{"name":"Travere Therapeutics, Inc. , San Diego, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Juntendo University Faculty of Medicine , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,25]]},"reference":[{"key":"2024083002380216200_bib1","first-page":"694","article-title":"[Intercapillary deposits of IgA-IgG]","volume":"74","author":"Berger","year":"1968","journal-title":"J Urol Nephrol (Paris)"},{"key":"2024083002380216200_bib2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.semnephrol.2018.05.013","article-title":"Epidemiology of IgA nephropathy: a global perspective","volume":"38","author":"Schena","year":"2018","journal-title":"Semin Nephrol"},{"key":"2024083002380216200_bib3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10157-011-0552-8","article-title":"A treatment dilemma in adult immunoglobulin A nephropathy: what is the appropriate target, preservation of kidney function or induction of clinical remission?","volume":"16","author":"Imai","year":"2012","journal-title":"Clin Exp Nephrol"},{"key":"2024083002380216200_bib4","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2024083002380216200_bib5","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1046\/j.1523-1755.2001.0590031077.x","article-title":"Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy","volume":"59","author":"Hiki","year":"2001","journal-title":"Kidney Int"},{"key":"2024083002380216200_bib6","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/ki.2015.252","article-title":"New developments in the genetics, pathogenesis, and therapy of IgA nephropathy","volume":"88","author":"Magistroni","year":"2015","journal-title":"Kidney Int"},{"key":"2024083002380216200_bib7","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/00007890-198204000-00006","article-title":"Fate of four cadaveric donor renal allografts with mesangial IgA deposits","volume":"33","author":"Sanfilippo","year":"1982","journal-title":"Transplantation"},{"key":"2024083002380216200_bib8","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00281-021-00883-8","article-title":"IgA glycosylation and immune complex formation in IgAN","volume":"43","author":"Suzuki","year":"2021","journal-title":"Semin Immunopathol"},{"key":"2024083002380216200_bib9","first-page":"1","article-title":"IgA nephropathy. From molecules to men","volume":"126","author":"Tomino","year":"1999","journal-title":"Contrib Nephrol"},{"key":"2024083002380216200_bib10","doi-asserted-by":"crossref","first-page":"P3","DOI":"10.1159\/000066656","article-title":"The renin-angiotensin system and progression of renal disease: from hemodynamics to cell biology","volume":"93","author":"Wolf","year":"2003","journal-title":"Nephron Physiol"},{"key":"2024083002380216200_bib11","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1681\/ASN.2007050607","article-title":"Renin-angiotensin system blockade is renoprotective in immune complex-mediated glomerulonephritis","volume":"19","author":"Guo","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"2024083002380216200_bib12","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1139\/Y08-059","article-title":"Endothelin: 20 years from discovery to therapy","volume":"86","author":"Barton","year":"2008","journal-title":"Can J Physiol Pharmacol"},{"key":"2024083002380216200_bib13","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00467-020-04518-2","article-title":"Endothelin-targeted new treatments for proteinuric and inflammatory glomerular diseases: focus on the added value to anti-renin-angiotensin system inhibition","volume":"36","author":"Benigni","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"2024083002380216200_bib14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1046\/j.1523-1747.2001.01256.x","article-title":"Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1","volume":"116","author":"Shi-Wen","year":"2001","journal-title":"J Invest Dermatol"},{"key":"2024083002380216200_bib15","doi-asserted-by":"crossref","first-page":"S224","DOI":"10.1097\/01.fjc.0000166260.35099.d5","article-title":"Comparison of endothelin-A and endothelin-B receptor distribution visualized by radioligand binding versus immunocytochemical localization using subtype selective antisera","volume":"44","author":"Kuc","year":"2004","journal-title":"J Cardiovasc Pharmacol"},{"key":"2024083002380216200_bib16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.33549\/physiolres.933670","article-title":"Molecular profiling in IgA nephropathy and focal and segmental glomerulosclerosis","volume":"67","author":"Tycov\u00e1","year":"2018","journal-title":"Physiol Res"},{"key":"2024083002380216200_bib17","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0272-6386(12)80031-X","article-title":"Angiotensin II local hyperreactivity in the progression of IgA nephropathy","volume":"21","author":"Coppo","year":"1993","journal-title":"Am J Kidney Dis"},{"key":"2024083002380216200_bib18","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1111\/j.1523-1755.2004.00874.x","article-title":"Mesangial expression of angiotensin II receptor in IgA nephropathy and its regulation by polymeric IgA1","volume":"66","author":"Lai","year":"2004","journal-title":"Kidney Int"},{"key":"2024083002380216200_bib19","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/MNH.0000000000000716","article-title":"Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease","volume":"30","author":"Smeijer","year":"2021","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2024083002380216200_bib20","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","article-title":"Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial","volume":"401","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"key":"2024083002380216200_bib21","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephorpathy (PROTECT): 2-year results from a randomized, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet"},{"key":"2024083002380216200_bib22","doi-asserted-by":"crossref","first-page":"R877","DOI":"10.1152\/ajpregu.00425.2015","article-title":"Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease","volume":"310","author":"Komers","year":"2016","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"2024083002380216200_bib23","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1681\/ASN.2011121160","article-title":"Development of a model of early-onset IgA nephropathy","volume":"23","author":"Okazaki","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2024083002380216200_bib24","doi-asserted-by":"crossref","first-page":"17926","DOI":"10.1038\/s41598-018-36159-9","article-title":"Chronic intermittent hypoxia-mediated renal sympathetic nerve activation in hypertension and cardiovascular disease","volume":"8","author":"Takahashi","year":"2018","journal-title":"Sci Rep"},{"key":"2024083002380216200_bib25","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1681\/ASN.2019100987","article-title":"Crucial role of AIM\/CD5L in the development of glomerular inflammation in IgA nephropathy","volume":"31","author":"Takahata","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2024083002380216200_bib26","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.kint.2019.01.031","article-title":"A proliferation inducing ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy","volume":"96","author":"Myette","year":"2019","journal-title":"Kidney Int"},{"key":"2024083002380216200_bib27","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet"},{"key":"2024083002380216200_bib28","doi-asserted-by":"crossref","first-page":"908","DOI":"10.2215\/CJN.00560122","article-title":"Endothelin receptor antagonists for kidney protection: lessons from the SONAR trial","volume":"17","author":"Heerspink","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024083002380216200_bib29","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1161\/HYPERTENSIONAHA.110.167486","article-title":"Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease","volume":"57","author":"Dhaun","year":"2011","journal-title":"Hypertension"},{"key":"2024083002380216200_bib30","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3109\/0886022X.2011.647301","article-title":"Endothelin-1 and endothelin a receptor immunoreactivity is increased in patients with diabetic nephropathy","volume":"34","author":"Zanatta","year":"2012","journal-title":"Ren Fail"},{"key":"2024083002380216200_bib31","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/ki.2014.143","article-title":"Endothelin and endothelin antagonists in chronic kidney disease","volume":"86","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"key":"2024083002380216200_bib32","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1476-5381.2012.02070.x","article-title":"Endothelin-1 and the kidney\u2014beyond BP","volume":"167","author":"Dhaun","year":"2012","journal-title":"Br J Pharmacol"},{"key":"2024083002380216200_bib33","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.2337\/diabetes.54.7.2172","article-title":"Heparanase-1 gene expression and regulation by high glucose in renal epithelial cells: a potential role in the pathogenesis of proteinuria in diabetic patients","volume":"54","author":"Maxhimer","year":"2005","journal-title":"Diabetes"},{"key":"2024083002380216200_bib34","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.2337\/db15-1413","article-title":"Atrasentan reduces albuminuria by restoring the glomerular endothelial glycocalyx barrier in diabetic nephropathy","volume":"65","author":"Boels","year":"2016","journal-title":"Diabetes"},{"key":"2024083002380216200_bib35","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.kint.2019.05.007","article-title":"Endothelin receptor-A mediates degradation of the glomerular endothelial surface layer via pathologic crosstalk between activated podocytes and glomerular endothelial cells","volume":"96","author":"Ebefors","year":"2019","journal-title":"Kidney Int"},{"key":"2024083002380216200_bib36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/ckj\/sfs001","article-title":"Endothelin and the podocyte","volume":"5","author":"Barton","year":"2012","journal-title":"Clin Kidney J"},{"key":"2024083002380216200_bib37","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1681\/ASN.2013040362","article-title":"\u03b2-arrestin-1 drives endothelin-1-mediated podocyte activation and sustains renal injury","volume":"25","author":"Buelli","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2024083002380216200_bib38","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1172\/JCI71195","article-title":"Endothelial mitochondrial oxidative stress determines podocyte depletion in segmental glomerulosclerosis","volume":"124","author":"Daehn","year":"2014","journal-title":"J Clin Invest"},{"key":"2024083002380216200_bib39","doi-asserted-by":"crossref","first-page":"646650","DOI":"10.3389\/fimmu.2021.646650","article-title":"The role of renal macrophage, AIM, and TGF-\u03b21 expression in renal fibrosis progression in IgAN patients","volume":"12","author":"Yang","year":"2021","journal-title":"Front Immunol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfae021\/56912363\/gfae021.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/39\/9\/1494\/58962963\/gfae021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/39\/9\/1494\/58962963\/gfae021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T02:38:35Z","timestamp":1724985515000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/39\/9\/1494\/7589744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":39,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,1,25]]},"published-print":{"date-parts":[[2024,8,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfae021","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,1,25]]}}}